StockTipsArenaBeta

BUY Laurus Labs Ltd — Rajesh Agarwal, AUM Capital

BUYLaurus Labs Ltd
Laurus Labs share price target & all analyst calls

byRajesh Agarwal, AUM CapitalHorizon: NA (inferred 1 year)29 Oct 2026via CNBC Awaaz.

Entry₹2,246.6Inferred
Target₹2,500
Total upside +11.28%
Stop lossNot given
CMP₹2,405.56h ago
Active+7.07%+3.93%upside left 12 mo left
Follow Rajesh Agarwal for new callsGet alertsWatch LAURUSLABS for new buy/sell callsGet alertsSee 10 other Long-term calls on LAURUSLABSSee 411 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Oct, 10:20 pm IST
17 supporting9 neutral1 opposing
Supports the BUY call (17)

Laurus Labs share price at record high after Q2 results 20⁠⁩26, dividend announcement - Should you buy pharma stock?

NewsLivemint·30 Oct · today

(opens in new tab)

Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY

NewsEt-Markets·30 Oct · today

(opens in new tab)

Laurus Labs hits 52-week high as strong Q2 results fuel buying

NewsHbl·30 Oct · today

(opens in new tab)

Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell

NewsNdtv-Profit·30 Oct · today

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·30 Oct · today

Neutral / worth noting (9)

Sensex, Nifty extend gains for 2nd day: IT stocks lead rally, broader market underperforms

NewsCnbc-Tv18·30 Oct · today

(opens in new tab)

Laurus Labs Limited has informed the Exchange regarding a press release dated October 29, 2026, titled "Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.".

NSE · Press Release·29 Oct · yesterday

(opens in new tab)

Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·29 Oct · yesterday

(opens in new tab)

Laurus Labs invested INR 1.078 billion in its joint venture KRKA Pharma Private Limited via a rights issue, maintaining its 49% stake.

BSE · Company Update·14 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

2 other SEBI-registered advisors have active long-term SELL calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·30 Oct · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Laurus Labs

All analyst calls on Laurus Labs

More from Rajesh Agarwal, AUM Capital

Every call and its outcome